<div id="readability-page-1"><p>American Trust raised its stake in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 36.8% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 23,890 shares of the company's stock after purchasing an additional 6,421 shares during the period. American Trust's holdings in AbbVie were worth $4,434,000 at the end of the most recent quarter.</p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p>A number of other institutional investors have also bought and sold shares of ABBV. Marshall &amp; Sullivan Inc. WA bought a new stake in shares of  AbbVie during the second quarter valued at about $25,000.  Evolution Wealth Management Inc. purchased a new stake in shares of  AbbVie in the 2nd quarter valued at $26,000.  TD Capital Management LLC lifted its stake in shares of  AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares during the last quarter.  Spurstone Advisory Services LLC purchased a new stake in  AbbVie in the second quarter worth $28,000.  Finally, Financial Gravity Companies Inc. purchased a new stake in  AbbVie in the second quarter worth about $36,000. Institutional investors own  70.23% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>ABBV has been the topic of a number of analyst reports. Guggenheim upped their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Wall Street Zen upgraded AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday. Cantor Fitzgerald  set a $250.00 price objective on shares of AbbVie and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 9th. BMO Capital Markets raised their target price on shares of AbbVie from $215.00 to $240.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, September 12th. Finally, Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued  a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $244.55.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p><b>View Our Latest Report on AbbVie</b></p><h2>AbbVie Trading Down 0.2%</h2><p>Shares of ABBV opened at $223.45 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The firm's fifty day moving average is $227.25 and its two-hundred day moving average is $209.95. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock has a market cap of $394.92 billion, a PE ratio of 169.28, a price-to-earnings-growth ratio of 1.21 and a beta of 0.36. </p><ul><li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  Research analysts forecast that  AbbVie Inc. will post 12.31 earnings per share for the current fiscal year. </p><h2>AbbVie Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie's previous quarterly dividend of $1.64. AbbVie's payout ratio is 496.97%. </p><h2>AbbVie Company Profile</h2> (Free Report)<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>See Also</h2><ul><li>Five stocks we like better than AbbVie</li><li>NYSE Stocks Give Investors a Variety of Quality Options </li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>American Trust increased its stake in AbbVie Inc. by 36.8% in Q2, now holding shares worth $4.43 million. Several other institutional investors also bought shares. Analysts have given AbbVie a consensus rating of 'Moderate Buy' with an average price target of $244.55. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, and increased its quarterly dividend to $1.73. The company has a market cap of $394.92 billion and a PE ratio of 169.28.</p>

American Trust Has $4.43 Million Stock Holdings in AbbVie Inc. $ABBV